Therapy update in nerve, neuromuscular junction and myopathic disorders.
OBJECTIVE
The objective of this review is to summarize recent advances in the treatment of various neuromuscular disorders including neuropathies, neuromuscular junction disorders, and myopathies.


RESULTS
Immunotherapy with sophisticated agents for myasthenia gravis and inflammatory myopathies, neuroprotection with vitamin E for chemotherapy-induced neuropathy, and promising gene transfer and exon-skipping therapies for muscular dystrophy are among the most exciting recent developments in the treatment of neuromuscular disorders.


CONCLUSIONS
In spite of significant advances, therapy in many neuromuscular diseases remains far from satisfactory. Better understanding of the underlying molecular and pathophysiologic processes for both hereditary and acquired disorders should lead to more refined and successful therapeutic approaches, reducing physical and other types of disability while posing fewer side effects.
Sadeghian
Hamid
H
Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-8897, USA.
Wolfe
Gil I
GI
D006801:Humans; D009135:Muscular Diseases / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D009468:Neuromuscular Diseases / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D020511:Neuromuscular Junction Diseases / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*